These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Recurrent epithelial ovarian cancer: an update on treatment. Foley OW; Rauh-Hain JA; del Carmen MG Oncology (Williston Park); 2013 Apr; 27(4):288-94, 298. PubMed ID: 23781692 [TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892 [TBL] [Abstract][Full Text] [Related]
4. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT; Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219 [TBL] [Abstract][Full Text] [Related]
5. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815 [TBL] [Abstract][Full Text] [Related]
6. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance. Chuang YT; Chang CL Taiwan J Obstet Gynecol; 2012 Sep; 51(3):336-41. PubMed ID: 23040913 [TBL] [Abstract][Full Text] [Related]
7. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917 [TBL] [Abstract][Full Text] [Related]
8. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory therapy in refractory/recurrent ovarian cancer. Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718 [TBL] [Abstract][Full Text] [Related]
10. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality? Tomao F; D'Incalci M; Biagioli E; Peccatori FA; Colombo N Cancer; 2017 Sep; 123(18):3450-3459. PubMed ID: 28678350 [TBL] [Abstract][Full Text] [Related]
11. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Monk BJ; Coleman RL Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937 [TBL] [Abstract][Full Text] [Related]
13. The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer. Lorusso D; Fontanella C; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F Expert Opin Drug Saf; 2017 Jun; 16(6):687-696. PubMed ID: 28471247 [TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center. Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410 [TBL] [Abstract][Full Text] [Related]
15. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Tan DS; Kaye SB Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149 [TBL] [Abstract][Full Text] [Related]
17. An overview of early investigational therapies for chemoresistant ovarian cancer. Marchetti C; Ledermann JA; Benedetti Panici P Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420 [TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes. Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886 [TBL] [Abstract][Full Text] [Related]